#South Korea #Seoul #Genentech #Hanmi Pharm #Obesity Therapy

Hanmi Pharm and Genentech Partnership: A New Era in Obesity Treatment

In a significant advancement in metabolic health management, Hanmi Pharm has officially announced its exclusive licensing agreement with Genentech, a member of the Roche Group, to collaborate on the development of the innovative therapy, HM17321. This agreement comes at a pivotal time in the treatment landscape for obesity and associated metabolic conditions, promising a fresh approach that could potentially reshape the future of weight management therapies.

What is HM17321?

HM17321, a proprietary analog of urocortin-2 (UCN2), boasts a non-incretin mechanism of action that sets it apart from existing therapies on the market. Unlike GLP-1 (glucagon-like peptide-1) based treatments, which primarily focus on weight reduction through mechanisms that also reduce lean body mass, HM17321 aims to promote weight loss while preserving essential muscle mass. This unique approach not only addresses obesity but may also mitigate associated conditions, including type 2 diabetes and cardiovascular diseases.

Promising Preclinical Results

Preclinical studies of HM17321 have yielded encouraging results, documenting both qualitative and quantitative improvements in weight management when administered alone or in combination with existing GLP-1 therapies. Its peptide-based structure also opens up possibilities for fixed-dose combination products, marking a significant step forward in multi-faceted treatment approaches.

Timeline and Next Steps

In November 2025, Hanmi Pharm received Investigational New Drug (IND) clearance from the U.S. FDA, allowing it to initiate Phase 1 clinical trials for HM17321. The ongoing clinical study aims to evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of this promising new therapy in healthy volunteers as well as individuals impacted by obesity. Following the completion of the Phase 1 trial, Genentech is set to assume responsibility for advancing HM17321 through Phase 2 clinical trials and beyond.

The Industry Response

In-Young Choi, Senior Executive Vice President at Hanmi Pharm, expressed excitement regarding the agreement, stating, "The paradigm of obesity treatment is evolving beyond simple weight reduction toward improving body composition and restoring metabolic health. The recognition of HM17321’s unique scientific mechanism and its potential in the global market is an encouraging validation of our efforts."

Adding to Choi's sentiments, Boris L. Zaïtra, head of Roche Corporate Business Development, noted the strategic importance of this licensing deal: "With our expanding pipeline focusing on cardiometabolic health, this next-generation therapy from Hanmi provides a distinctive approach to targeting obesity while enhancing muscle mass and function. We are eager to further develop this medicine to meet the urgent needs of those affected by obesity and related metabolic disorders."

Financial Aspects of the Agreement

The terms of the licensing agreement outline an upfront payment of $190 million from Genentech, with the total deal potentially reaching up to $2.3 billion. This valuation includes various milestone payments tied to the development, regulatory progress, and commercial success of HM17321, along with tiered royalties dependent on future sales.

In conclusion, the partnership between Hanmi Pharm and Genentech signals a promising shift in the obesity treatment landscape, blending innovative science with a commitment to addressing complex metabolic challenges. This collaboration not only showcases the potential of newly developed therapeutics like HM17321 but also highlights the importance of understanding metabolic health in an era where obesity is increasingly recognized as a critical public health issue.